OFI Invest Asset Management Invests $945,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

OFI Invest Asset Management bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,300 shares of the medical research company's stock, valued at approximately $945,000.

Other hedge funds have also made changes to their positions in the company. Versant Capital Management Inc lifted its holdings in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Assetmark Inc. raised its stake in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after purchasing an additional 173 shares during the last quarter. Pinnacle Bancorp Inc. raised its position in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International during the third quarter valued at approximately $59,000. Finally, ORG Wealth Partners LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $56,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Charles River Laboratories International Stock Down 2.1 %

Shares of NYSE:CRL traded down $3.56 during mid-day trading on Thursday, hitting $167.03. 1,129,939 shares of the company traded hands, compared to its average volume of 708,136. The firm has a market cap of $8.54 billion, a P/E ratio of 1,113.55, a PEG ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $274.77. The firm's 50 day simple moving average is $168.35 and its 200 day simple moving average is $185.07.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's revenue was down 1.1% on a year-over-year basis. During the same period last year, the business posted $2.46 EPS. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on CRL shares. Barclays cut their price target on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a report on Tuesday, February 18th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Robert W. Baird lowered their price target on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Finally, UBS Group restated a "neutral" rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $198.36.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).